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Very low dose myocardial perfusion imaging with 1 mSv using cad-
mium-zinc-telluride (CZT) cameras and Tc99m-sestamibi 
Bernard Songy [Orateur] , Ornella Mirensky, David Lussato, Mathieu
Queneau, Mohamed Guernou
Centre Cardiologique du Nord, Imagerie Scintigraphique, Saint Denis, France
Background: Myocardial perfusion imaging is an essential tool for man-
agement of coronary artery disease but leads to relative high radiation expo-
sure (average: 20 mSv, Berrington de Gonzalez, Circulation 2010) and
contributes up to 20% of the estimated annual collective radiation dose. We
previously published validation of new CZT cardiac cameras, improvement of
diagnosis performances and reduction of dosimetry lower than 10 mSv with
thallium (JESFC 2011).
Objectives: We used new cardiac CZT cameras to decrease to only 1 mSv
the effective dose with technetium agents. 
Methods: We prospectively studied 100 consecutive patients without pre-
viously known coronary artery disease referred for diagnostic stress myocar-
dial perfusion imaging. We injected at stress a low dose of Tc99m-sestaMIBI
(1.75 MBq/kg), performed immediate stress myocardial scan in 10 mn with a
CZT camera GE DNM 530c. We practiced rest myocardial scan 4 hours later
only when stress images were abnormal, with injection of a treble activity.
Results: Patients were 59 males and 41 females.There weight was 78±15
kg. They received at stress 135±30 MBq of Tc99m-sestaMIBI. Total and
myocardial acquired counts were 1092±308 kcts and 317±91 kcts. Quality of
scan was excellent in 82 cases and acceptable in other cases. The results were
normal in 90 cases and abnormal in 10 cases (3 artifacts,4 ischemia and 3
unknown myocardial infarction scar). Normal stress ejection fraction was 68±
7%, end-diastolic and end-systolic volumes were 72±27 and 23±11 ml. The
effective dose at stress was 0.79±0.08 mSv for men and 1.02±0.07 mSv for
women. The rest activity (average 430 MBq) leads to an additional dose of
3.02 mSv for men and 3.89 mSv for women.
Conclusions: With reduced activities of Tc99m-sestaMIBI, CZT cameras
give high quality imaging. It leads to a decrease of equivocal results and a low
ratio of patients needing an additional rest scan. The effective dose is thus
very low, less or equal to 1 mSv in most cases.
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Pro-adrenomedullin (MR-proADM) can predict short and long term
mortality in STEMI patients
Johanne Silvain [Orateur] (1), Farzin Beygui (1), Maguy Bernard (2),
Guillaume Cayla (1), Stephen A. O’Connor (2), Anne Bellemain-Appaix
(1), Olivier Barthelemy (1), Delphine Brugier (3), Jean-Philippe Collet
(1), Gilles Montalescot (1)
(1) AP-HP, CHU Pitié-Salpêtrière, Cardiologie, Paris, France – (2) AP-
HP, CHU Pitié-Salpêtrière, Laboratoire de Biochimie, Paris, France – (3)
Inserm UMRS 937, Institut de Cardiologie, Paris , France
Background: Midregional pro-Adrenomedulin (MR-proADM) appears to
be a powerful predictor of adverse outcome after AMI when measured 3 to 5
days after symptoms onset.
Objectives: We sought to assess whether (MR-proADM) measured at
admission would correlate with the outcome in ST-segment elevation myocar-
dial infarction patient treated with primary PCI. 
Methods: We measured plasma MR-proADM in 283 consecutive STEMI
patients (74.8% men, mean age 64.2 ± 15 years) immediately after the sheath
insertion and before the primary PCI. We assessed the relation between MR-
proADM and mortality (in-hospital and 1year of follow-up) and compared
them to the prognostic value of troponin I (peak value) and the TIMI risk
Score for STEMI patients.
Results: All cause mortality was 4.5% at discharge and 7.3% at the end of
the follow-up (365 days). The MR-proADM was increased in patients who
died compared with survivors (median 1.27 nmol/l, IQR [0.99 to 3.16 nmol/
l], vs. 0.53 nmol/l, range 0.39 to 0.68 nmol/l], p < 0.0001). 
The areas under the receiver-operating characteristic curve for long-term
survival (one year) for MR-proADM, Troponin I (peak value in μg/l) and
TIMI Risk Score were 0.79 (0.64-0.95) p<0.001, 0.58 (0.49-0.68) p=0.06, and
0.67 (0.55-0.79) p=0.01 respectively. 
Findings were similar for in-hospital mortality 0.77 (0.55-0.98) p=0.002
for MR-proADM. 
Conclusions: Early measurement of MR-proADM during the acute phase
of AMI is a powerful predictor of short and long term mortality in STEMI
patients.
The MR-proADM may represent a clinically useful marker of prognosis
during AMI. 
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Impact of the systematic use of DES on the clinical outcome in diabe-
tic patients
I. Jousten [Orateur], A. Raptis, Jacques Jamart, P. Chenu, V. Dangoisse,
L. Gabriel, A. Guedes, B. Marchandise, Erwin Schroeder
CHU Mont-Godinne, Cardiology, Yvoir, Belgium
Background: In November 2003, DES were reimbursed by the belgian
Health Insurance System for diabetic patients, based on their higher restenosis
rate after BMS implantation and improved outcome in randomized trials.
Aim: To assess the impact of the systematic use of DES in diabetic
patients on procedural management and clinical outcome (= stent thrombosis,
TL revascularization and death). 
Methods: We compared procedural data and outcome in consecutive series
of 366 (1.1.2000 1.11.2003) PCI procedures (hospital stays) by BMS versus
276 PCI procedures with at least one DES (1.11.2003 30.6.2006) performed
at our institution.
Results: Outcome data after hospital discharge are based on Kaplan-Meier
survival curves. 
Stent thrombosis includes definite, probable and possible cases.
Conclusion: In our consecutive series, the beneficial effect of systematic
DES implantation on repeat TLR in diabetic patients was less impressive than
expected, based on previous randomized trials. However, the rate of stent
thrombosis was not increased. Overall mortality was not reduced (at 4 y.)
despite better secondary prevention measures. Changes in revascularization
strategies in diabetic patients (indications, procedural) may explain partially
the reduction of the expected benefit by systematic use of DES in routine clin-
ical practice in this single center all-comes registry.
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Do mortality predictors differ according to reperfusion strategy in acute
myocardial infarction patients?
Ismail Ghérissi [Orateur], Wiem Selmi, Fatma Ben Amor, Z Dridi, Meriem
Khrouf, Walid Saieb, Samer Hamayel, Ayoub Ghrairi, Semi Bouraoui, Amine
Hdiji, M Hassine, Abdennaim Hajlaoui, Fethi Betbout, Habib Gamra
Fattouma Bourguiba University Hospital, Cardiology, Monastir, Tunisia
Background: Up to date treatment of ST elevation myocardial infarction
(STEMI) has been based on as early as possible reperfusion that can be
achieved by either primary angioplasty (PAMI) or thrombolysis. 
Predictors of mortality of these two strategies may not be similar. The aim
of this analysis was to identify mortality predictors in STEMI patients (pts)
according to the reperfusion strategy.
Methods: A total of 1353 pts admitted for acute myocardial infarction
(AMI) between January 1995 and April 2011 were included in our MIRAMI
(MonastIR Acute Myocardial Infarction) registry. Reperfusion therapy was
given to 788 (58.2%) pts. Because of lacking data, 117 were excluded, the
remaining 671 pts were considered for this analysis: 372 pts received throm-
bolytics and 299 underwent primary angioplasty. In each group, an univariate
then a multivariate logistic regression analysis was used to evaluate the impact
on mortality of the following factors: age, sex, hypertension, diabetes,
smoking, infarct location, Killip class, time to treatment (TTT), hemoglobin
and creatinin serum levels.
Results: Among the tested parameters, only four were identified to be
independent predictors of mortality by multivariate analysis as shown below:
Conclusion: In our MIRAMI registry, regardless of the reperfusion
strategy, mortality predictors were: time to treatment > 6 hours, heart failure
and renal impairment. Hemoglobin blood level less than 12g/dl was an inde-
pendent predictor only in the primary angioplasty group.
Table – Results
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Cardiovascular risk in clopidogrel-treated patients according to cyto-
chrome P450 2C19*2 loss-of-function allele and proton pump inhibi-
tor coadministration
Leila Abid [Orateur] (1), Lobna Laroussi (1), Nouha Abdelmoula (2), Najla
Kharrat (3), Rania Abdelhédi (3), Mourad Hentati (4), Samir Kammoun (5)
(1) CHU Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) Histology Labora-
tory, FMS, Sfax, Tunisia – (3) CBS Center , Sfax, Tunisia – (4) CHU Hédi
Chaker, Sfax, Tunisie – (5) CHU Hédi Chaker, Cardiologie, Sfax, Tunisia
Background. Clopidogrel is an antiplatelet drug that requires bioactivation
to its active metabolite to demonstrate its antiplatelet effect. Formation of the
active metabolite involves multiple cytochrome P450 enzymes, with
CYP2C19 playing an important role. Clopidogrel is often co-administered
with proton pump inhibitors (PPIs) to decrease gastro intestinal-tract bleeding.
The aim of this study was to assess the association between the loss-of-
function cytochrome P450 2C19 (CYP2C19)*2 variant, the use of proton
pump inhibitors (PPIs) and ischemic outcomes (major adverse cardiovascular
events [MACE]) in patients treated with clopidogrel.
Methods. Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results. 75% of our patients were on PPIs in the hospital phase distributed
equally between the two groups non mutated and mutated (74% vs 78.3%
p=0.68). The use of PPIs in the hospital phase did not cause a significant
increase in the occurrence of MACE (p=0.23).
In the group of patients on PPIs, no statistically significant difference was
observed regarding the occurrence of intra hospital MACE according to genetic
profile (5, 3% in the non mutated group versus 5,6% in the mutated group).
Conclusion. The present study provides further supportive evidence to
indicate that PPIs can be used safely in patients taking clopidogrel. Although
omeprazole might attenuate some of the in vitro antiplatelet effects of clopi-
dogrel, convincing evidence is currently lacking to indicate that this combina-
tion places patients at increased risk of harm.
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Angiotensinogen gene polymorphism associates with acute myocardial
infarction risk in Tunisian patients 
Soumira Mehri, Sonia Hammami [Orateur] , Nadia Koubaa, Amel Nkbi,
Mohamed Hammami
Faculté de Médecine Monastir, Nutrition Humaine et désordres métaboliques,
Monastir, Tunisie
Introduction. To explore the role of genetic variant of angiotensinogen
(AGT) M235T as an independent risk factor for acute myocardial infarction
(AMI) and to investigate the possible association with the severity of coronary
artery disease (CAD), estimated on the basis of the number of coronary ste-
noses and critical arterial occlusions. 
Patients and methods. 123 AMI patients compared to 144 healthy
controls. AGT genotypes were determined by PCR method.
Results. A significant association was found between AGT M235T poly-
morphism and AMI (p=0.021). By logistic regression, the TT genotype
appeared to confer 1.9-fold increased risk for AMI in both the univariate and
the multivariate model. The frequencies of TT genotype and T allele increased
with the number of stenoses in coronary vessels. Moreover, the TT genotype
and the T allele were more frequent in the subgroup of patients with stenoses
in at least four coronary vessels than in other patients including subjects with
one to three vessel disease. Furthermore, the TT genotype and the T allele
were significantly more frequent in patients with critical arterial occlusions
(>90%) than in subjects without critical stenoses. 
Conclusions. The AGT M235T polymorphism associates with AMI risk
and influences CAD severity. 
BMS group
n=366
DES group
n=276
p
BMS vs DES
Age (y.)
BMI
Insuline (%)
Antihypertensive therapy (%)
Hypolipemic therapy (%)
Prior CVD 
LV Ej. Fraction >50% (%)
Anti-GP IIB IIIA before
Number of stents/procedure
Number of segments/procedure
Stent length/procedure
Hospital mortality (%)
64.8
29.8
26.0
49.5
39.6
10.9
71.6
5.2
1.5
1.6
22.8
2.5
65  
29.9
21.0
57.2
51.1
16.3
78.7
10.5
1.7
1.7
23.6
1.1
NS
NS
NS
=0.05
<0.01
<0.05
=0.05
=0.01
=0.01
NS
NS
NS
Stent thrombosis (%) 1 y.
4 y. 
Repeat TLR (%) 1 y.
4 y.
Overall death (%) 1 y.
4 y. 
5,0
7.5
14.9
22.5
9,0
17.0
5.1
7.1
7.1
16.0
9.0
24.0
NS
=0.09
NS
TTT>6 hours Killip class ≥2 Creatinin 
>150μmol/l
Hemoglobin
<12g/dl
Thrombolysis 
group
p=0.03
OR=3.28
p=0.0001
OR:2.9 to 17.17
p=0.014
OR=4.39
NS
PAMI group p=0.036
OR=2.8
p<0.001
OR: 4.41 to 19.21
p=0.006
OR=4.93
p=0.003
OR=3.96
